Know Cancer

or
forgot password

Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer


N/A
40 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer


Inclusion Criteria:



- Postmenopausal women

- Diagnosed with hormone-receptor positive breast cancer

- Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen,
Anastrozole, Exemestane, and/or Letrozole

- Good command of the English language

- Under the care of a medical oncologist at Princess Margaret Hospital

Exclusion Criteria:

- Previously received chemotherapy

- Recurrent and/or metastatic disease

- History of endocrine, dermatology, or immune system disorders known to alter hair
growth (ie. Hypothyroidism and iron deficiency)

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Outcome Measure:

Severity of Alopecia Tool (SALT)

Outcome Description:

The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Lindsay Carlsson

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Health Network-Princess Margaret Hospital

Authority:

Canada: Research Ethics Board

Study ID:

Alopecia

NCT ID:

NCT01300871

Start Date:

January 2011

Completion Date:

Related Keywords:

  • Breast Cancer
  • Alopecia
  • Breast Neoplasms

Name

Location